US Patent

US11517573 — Therapeutic compositions, combinations, and methods of use

Method of Use · Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2040-09-11 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using a FAK inhibitor in combination with a dual RAF/MEK inhibitor to treat abnormal cell growth, such as cancer, in a subject.

USPTO Abstract

This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4196`	—

Patent Metadata

Patent number: US11517573
Jurisdiction: US
Classification: Method of Use
Expires: 2040-09-11
Drug substance claim: No
Drug product claim: No
Assignee: Institute of Cancer Research Royal Cancer Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.